Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
285.4 SEK | +0.71% | +8.60% | +6.89% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2024 P/E ratio at 29.17 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 4.53 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.89% | 8.83B | B+ | ||
-4.24% | 86.85B | A- | ||
+2.76% | 40.16B | A- | ||
-16.48% | 31.28B | B- | ||
+57.86% | 25.27B | A | ||
-13.58% | 15.33B | C | ||
-9.12% | 11.96B | D+ | ||
-42.56% | 11.61B | B | ||
-10.53% | 7.94B | B- | ||
+1.55% | 7.58B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SOBI Stock
- Ratings Swedish Orphan Biovitrum AB